BenzingaAugust 26, 2026 at 10:25 PM NY8 days ago
AbbVie Submits EMA Application For SKYRIZI Subcutaneous Induction In Adults With Moderately To Severely Active Crohn's Disease, Backed By Phase 3 AFFIRM Data
Submission supported by data from Phase 3 pivotal AFFIRM studyIf approved, adult Crohn's disease patients will have an additional option for induction of risankizumab which is already approved for intravenous (IV)
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga
Companies in This Story
Related Stories
Which dow jones stocks are moving on Friday?
ChartMill4 hours ago
Exploring the top movers within the S&P500 index during today's session.
ChartMill4 hours ago
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo4 hours ago
Sector Update: Financial
Yahoo6 hours ago
Should You Buy, Sell or Hold PVH Stock Post Q2 Earnings?
Yahoo6 hours ago